Abstract: A simple, rapid and sensitive RP-HPLC method for the quantification of pioglitazone hydrochloride in bulk drug and tablet formulation was developed and validated. Chlordiazepoxide was used as internal standard. The separation was achieved on a Nucleodur 100-5 C18 column (250 mm× 4.6 mm i.d., 5 m particle size). The mobile phase consisted of methanol-0.07 M formic acid (57:43, v/v) at a flow rate of 0.9 mL/min and detection was performed at 266 nm using photodiode array (PDA) detector. The drug was subjected to various ICH prescribed stress conditions including hydrolysis (acid and alkaline), oxidation, photolysis and thermal degradation. Degradation in acid, base and peroxide was found in range 36-45%. The proposed method was validated with respect to specificity, linearity, accuracy, precision, limit of detection (LOD), limit of quantitation (LOQ), stability, and robustness as per ICH guideline. The developed method was found to be successively applied for the quality control of pioglitazone hydrochloride in bulk drug and tablets as well as the stability indicating studies.
INTRODUCTION
Pioglitazone hydrochloride (Figure 1 ), (±)-5-[p-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione monohydrochloride, is an oral antidiabetic agent used in the treatment of type 2 diabetes mellitus (also known as non-insulin-dependent diabetes mellitus [1, 2] (NIDDM) or adult-onset diabetes). Pioglitazone decreases insulin resistance in the periphery and liver, resulting in increased insulindependent glucose disposal and decreased hepatic glucose output. Few methods for the determination of pioglitazone hydrochloride were reported including voltammetry in tablets and biological fluids [3] , potentiometry in tablets [4] , extractive spectrophotometry in raw material and tablets [5] , HPLC in pharmaceutical formulations [6] [7] [8] [9] [10] [11] and in biological fluids [11] [12] [13] [14] . Pioglitazone hydrochloride has been determined in combination with other drugs using UV-spectrophotometry [15] [16] [17] , HPLC [15, [18] [19] [20] [21] in combined dosage forms, HPLC in formulations and human serum [22] [23] [24] [25] and LC-MS methods in human
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Year 2015 | Volume 3 | Issue 1 | Page 1-11 plasma [26] [27] [28] . United States Pharmacopoeia (USP) [29] employ HPLC method for the assay of pioglitazone hydrochloride in tablets. Further, the USP describes no environmentally friendly chromatographic procedure since acetonitrile is one of the components of mobile phase. The literature survey reveals that none is reported as a stability indicating assay method. Therefore, the aim of this study is focus on the development and validation of a rapid, sensitive and accurate stability-indicating RP-HPLC method for the determination of pioglitazone hydrochloride in bulk drug and tablet formulation with a simple composition, low cost of mobile phase and lower solvent consumption leads to an environmentally friendly chromatographic procedure. Chlordiazepoxide (Figure 1 ) was used as internal standard, to improve the analytical performance and thus control undetermined changes in active pharmaceutical ingredient concentration and instrument response fluctuations, and also to reduce the problem of the many-fold dilution required in the classical batch procedures. Additionally, forced degradation studies were achieved on the drug substance in accordance to the International Conference on Harmonization (ICH) guidelines [30] . The method serves as an alternative to the methods described in pharmacopoeias. 
EXPERIMENTAL

Materials
Pure drug samples of pioglitazone hydrochloride (PIO) and chlordiazepoxide (CLZ) were obtained from Dr Reddys and Centaur Pharmaceuticals PVT (India), respectively. The HPLC-grade methanol and water were purchased from Merck (Germany). Analytical reagent grade formic acid from Merck was used to prepare the mobile phase. Tablets were purchased from Syrian market, containing pioglitazone hydrochloride 15 or 30 mg per tablet.
HPLC system
The chromatographic system consisted of Hitachi (Japan) Model L-2000 equipped with a binary pump (model L-2130, flow rate range of 0.000-9.999 mL/min), degasser and a column oven (model L-2350, temperature range of 1-85 o C). All samples were injected using a Hitachi L-2200 autosampler (injection volume range of 0.1-100 L). Elutions of all analytes were monitored at 266 nm by using a Hitachi L-2455 absorbance detector (190-900 nm) containing a quartz flow cell (10mm path and 13L volume). Each chromatogram was analyzed and integrated automatically using the Ezchrom Elite Hitachi Software.
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Chromatographic conditions
Separation was achieved on a reversed phase Nucleodur 100-5 C18 column (250 × 4.6 mm, 5 m particle size,). The mobile phase was consisted of methanol/0.07 M formic acid (43/57, v/v) and was pumped at a flow rate of 0.9 mL/min. The mobile phase was filtered through a nylon 0.45 m membrane filter and degassed by ultrasonic agitation before use. The injection volume was 10 L. The system was operated at ambient temperature.
Standard solutions
Standard stock solution of PIO (1.0 mg/mL) was prepared by direct weighing of standard substance with subsequent dissolution in HPLC grade methanol. From this stock solution the working standard solution was prepared by further diluting of stock solution using methanol. Standard solution of CLZ (1.0 mg/mL) was prepared by dissolving appropriate amount of the compound in methanol. These solutions were stored in the dark at 2-8 °C and found to be stable for two weeks at least.
Assay procedure for dosage form
Twenty tablets containing PIO were weighed and finely powdered. Portions of the powder (each equivalent to the weight of five tablets) were accurately weighed into 50 mL volumetric flasks and 30 mL methanol was added. The volumetric flasks were sonicated for 15 min to effect complete dissolution of the PIO, the solutions were then made up to volume with methanol. The sample solutions were filtered through 0.45 m nylon filter. The aliquot portions of the filtrate were further diluted to get final concentration of 200 g/mL of PIO in the presence of 50 g/mL of internal standard. Finally, 10 L of each diluted sample was injected into the column and chromatogram was recorded for the same. Peak area ratios of PIO to that of CLZ were then measured for the determination of PIO concentrations in the samples and then calculated using peak data and standard curves.
Forced degradation studies
To evaluate the stability indicating properties of the developed HPLC method, forced degradation studies of PIO were executed in accordance with ICH guidelines as indicated below. Drug at a concentration of 0.2 mg/mL was used in all degradation studies. After degradation all solutions were diluted with methanol to yield starting concentration of 200 g/mL, filtered and then chromatographed along with a non-stressed sample.
Hydrolytic degradation study
Sample solutions were treated separately with 0.1 N HCl and 0.1 N NaOH at 75 °C for 1 h (in a heat block). The solutions were cooled and then neutralized as desirable (0.1 N NaOH or 0.1 N HCl).
Oxidative degradation study
Sample solutions were treated with solution of 3.0% (v/v) H 2 O 2 at 75 o C for 1 h and cooled.
Thermal degradation study
PIO powder was exposed to heat at 100 °C for 24 h in a convection oven, and then cooled. An amount of the powder was weighed and diluted as previously described.
Photo-degradation study
Active pharmaceutical ingredient (API) powder of PIO was prepared and exposed to UV-light up to 24 h. Approximately 100 mg of powder was spread on a glass dish in a layer that was less than 2 mm in Canadian Chemical Transactions thickness. Under UV-light, all samples were placed in a photo-stability chamber. The UV radiation is at 254 nm. All stressed samples were taken out periodically and prepared as previously described.
Method Validation
Linearity
A series of working standard drug solutions equivalent to 0.99-701.00 g/mL were prepared by diluting the stock standard solution with the methanol. In each sample 0.5 mL of CLZ was added (50 g/mL in the final volume). To construct the calibration curve five replicates (10 L) of each standard solution were injected immediately after preparation into the column and the peak area of the chromatograms were measured. Then, the mean peak area ratio of PIO to that of the internal standard was plotted against the corresponding concentration to obtain the calibration graph.
LOD and LOQ
The minimum level at which the investigated compounds can be reliably detected (limit of detection, LOD) and quantified (limit of quantitation, LOQ) were determined experimentally. LOD was expressed as the concentration of compound that generated a response to three times of the signal to-noise (S/N) ratio, and LOQ was 10 times of the S/N ratio [31] . The LOD and LOQ parameters were determined from regression equations of PIO; LOD (k=3) =k×S a /b, LOQ (k=10) =k×S a /b (where b is the slope of the calibration curve and S a is the standard deviation of the intercept).
Precision and accuracy
Intra and inter-day precision of the method were determined by performing replicate (n = 5) analyses of standards and samples. Intra-day assay variation was evaluated by injecting these samples in the same day. Inter-day assay variation was evaluated by injecting these samples on 3 different days from 1 to 15 after preparation. Recovery study was performed in view to justify accuracy of the proposed method.
Specificity
The specificity of the method was established through study of resolution factor of drug peaks from nearest resolving peak and also among all other peaks. Peak purity of PIO was assessed to evaluate the specificity of the method. Specificity was also studied by performing the forced degradation study using acid and alkali hydrolysis, chemical oxidation, dry heat and photo degradation studies.
Robustness
Robustness of HPLC method was determined by deliberately varying certain parameters like flow rate, percentage of organic solvent in mobile phase and pH of mobile phase. For all changes in conditions the samples were analysed in triplicate. When the effect altering one set of conditions was tested, the other conditions were held constant at optimum values.
System suitability
The system suitability test was performed to confirm that the LC system to be used was suitable for intended application. A standard solution containing 200 g/mL of PIO in the presence of 50 g/mL of internal standard was injected seven times. The parameters peak area, retention time, capacity factor, selectivity, resolution, theoretical plates, tailing factor (peak symmetry) and % RSD were determined.
RESULTS AND DISCUSSION
Method development and optimization of chromatographic conditions
When acetonitrile and water was used drug peak merged with solvent front. When methanol and
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water was used as mobile phase drug eluted late and had broadening. So buffer was used. When 65:35 ratio of methanol: formic acid 0.07 M was tried drug peak was near to solvent peak. An increase in the percentage of methanol decreases the retention of PIO and the internal standard, CLZ. Increasing methanol percentage to more than 70% PIO peak is eluted with the solvent front, while at methanol percentage lower than 50% the elution of CLZ peak is seriously delayed. The optimum methanol percentage was found to be 57%. So ratio of 57:43 methanol: formic acid 0.07 M was gave satisfactory result ( Figure 2 ). Nucledur100-5 C18 column gave the most suitable resolution between PIO and CLZ peaks (>4) according to the pharmacopeial requirement while the other columns (Nucleodur C8, Hichrom 5 C8, Nucleodur C18, ODS Hypersil C18) cause the peaks of the PIO and CLZ either to be overlapped or to have unsuitable resolution (<4).
The use of isocratic elution was proven to be short retention time for the PIO peak and helped in the separation of PIO, CLZ and degradation products. Figure 2 shows a typical chromatogram obtained by the proposed RP-HPLC method, demonstrating the resolution of the symmetrical peaks corresponding to PIO and CLZ with a flow rate of 0.9 mL/min. The retention time of PIO and CLZ was about 3.66, and 4.92 min, respectively. The retention time observed allows a fast determination of the drug, which is suitable for QC laboratories. The optimum wavelength for detection was at 266 nm, at which the best detector responses for all substances were obtained. 
Accelerated degradation
The results of the forced degradation study are given in Table 1 . PIO was found to be sensitive to acid hydrolysis. About 40% degradation of PIO was found when heating in 0.1 N HCl at 75 o C for 1 h. A chromatogram of the acid degraded standard solution is presented in Figure 3a . In alkali condition in 0.1 N NaOH at 75 o C for 1 h, about 45% of drug was degraded and produced a very minor unknown degradation product at 7.3 min as shown in Figure 3b . Upon heating the solution in H 2 O 2 3% at 75 o C for 1 h, PIO yielded a minor degradation product at 2.76 min, whereas the degradation of PIO was at 3.79
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Year 2015 | Volume 3 | Issue 1 | Page 1-11 min with an assay of 63.39% (Figure 3c ). PIO was found to be stable to the effect of light and temperature. When the drug powder was exposed to UV light for one day and to dry heat at 100 o C for one day, no decomposition of the drug was observed (Figure 3d ,e). 
Method validation
The method was validated according to ICH guidelines. The following validation characteristics were addressed:
System suitability
The system suitability requirements for PIO in the presence of CLZ was a % RSD for peak area less than 0.94, a peak tailing factor less than 1.14 and R s greater than 4.0 between adjacent peaks for the analyte. This method met these requirements. The results are shown in Table 2 .
Specificity
The specificity of the method was established through study of resolution factor of drug peaks from nearest resolving peak and also among all other peaks. The specificity of the chromatographic method was determined to ensure separation of PIO and CLZ as illustrated in Figure 2 where complete separation of PIO was noticed. The HPLC chromatogram recorded for the analyte in tablet (Figure 4) showed almost no peaks within a retention time range of 10 min. The figure show that PIO is clearly separated and the peak of analyte was pure and excipients in the formulation did not interfere the analyte.
Linearity and limits of detection and quantification
A linear calibration graph was obtained with correlation coefficient of the regression equation [32] greater than 0.999 in all cases and results are summarized in Table 3 . Calibration plot was linear for 0.99-701.00 µg/mL for PIO. LOD and LOQ were 0.16 and 0.54 g/mL, respectively, showed good sensitivity of the proposed method. 
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Accuracy and precision
Accuracy was determined by calculating the recovery. The method was found to be accurate with % recovery 100.03%-104.66% for PIO (Table 4) . Precision: a) Repeatability data are shown in Table 5 . The % RSD is < 2 for PIO which indicate that the method is precise. b) Variation of results within the same day (intra-day), variation of results between days (inter-day) was analyzed. For intra-day (n=5) % RSD was found to be 0.10-1.13% and % RSD for inter-day (n=5) was 0.13-1.43%. The % RSD is < 2 which indicate that the method is precise (Table 4) .
Robustness
The robustness was investigated by achieving deliberate changes in concentration of formic acid by ± 0.02 M, flow rate by ± 0.1 mL/min and change in methanol composition of mobile phase by ±2%. Robustness of the method was carried out in triplicate at a concentration of 200 g/mL. The system suitability parameters remained unaffected over deliberate small changes in the chromatographic system, illustrating that the method was robust over an acceptable working range of its HPLC operational parameters (Table 5 ). 
Method application
The proposed, developed and validated method was successfully applied to analysis of PIO in their marketed formulation (Figure 4 ). There was no interference of excipients commonly found in tablets as described in specificity studies. Student's t-test was used for statistical analysis of the data and statistical significance was defined at the level of P<0.05. The results obtained with the proposed method were compared with the official method [29] and have been shown in Table 6 . Good agreement with results obtained by the official method was observed. The proposed method is simple, rapid, accurate, highly sensitive and suitable for the routine quality control. 
CONCLUSION
This developed and validated method for analysis of PIO in pharmaceutical preparations is very rapid, accurate, and precise. The method was successfully applied for determination of PIO in its pharmaceutical tablet formulation with limit of detection of 0.16 g/mL. Moreover it has advantages of short run time and the possibility of analysis of a large number of samples, both of which significantly reduce the analysis time per sample. Hence this method can be conveniently used for routine quality control analysis of PIO in its pharmaceutical formulation. 
